Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82(3):532–7.
2. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170(4):974–9; discussion 979–80.
3. Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16(4):585–96.
4. Van Gorp T, Amant F, Neven P, et al. The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer. Cancer Treat Res. 2007;134:387–402.
5. Vergote I, van Gorp T, Amant F, et al. Neoadjuvant chemotherapy for ovarian cancer. Oncology (Williston Park). 2005;19(12):1615–22; discussion 1623–30.
Cited by
148 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献